Table 3 Cox regression analyses by HER2 status in 458 women with a primary DCIS
DCIS | ||
|---|---|---|
HER2 positive | HER2 negative | |
HR (95 % CI) | HR (95 % CI) | |
Ipsilateral Breast Events (IBE) | ||
BCS (n = 331) (events = 95) | ||
Univariate HR (95 % CI) | 1.20 (0.78–1.85) | (Ref) |
aAdjusted HR (95 % CI) | 1.27 (0.83–1.96) | (Ref) |
bAdjusted HR (95 % CI) | 1.17 (0.75–1.83) | (Ref) |
cAdjusted HR (95 % CI) | 1.22 (0.76–1.95) | (Ref) |
BCS, in situ IBEs (events = 49) | ||
Univariate HR (95 % CI) | 1.63 (0.92–2.89) | (Ref) |
aAdjusted HR (95 % CI) | 1.76 (0.99–3.11) | (Ref) |
bAdjusted HR (95 % CI) | 1.40 (0.77–2.54) | (Ref) |
cAdjusted HR (95 % CI) | 1.65 (0.88–3.11) | (Ref) |
BCS, invasive IBEs (events = 46) | ||
Univariate HR (95 % CI) | 0.78 (0.40–1.55) | (Ref) |
aAdjusted HR (95 % CI) | 0.83 (0.42–1.64) | (Ref) |
bAdjusted HR (95 % CI) | 0.87 (0.43–1.75) | (Ref) |
cAdjusted HR (95 % CI) | 0.80 (0.38–1.66) | (Ref) |
Invasive Breast Cancer Recurrence (IBCR) | ||
All patients (n = 420) (Events = 102) | ||
Univariate HR (95 % CI) | 0.60 (0.38–0.94) | (Ref) |
aAdjusted HR (95 % CI) | 0.58 (0.38–0.95) | (Ref) |
bAdjusted HR (95 % CI) | 0.59 (0.37–0.95) | (Ref) |
cAdjusted HR (95 % CI) | 0.59 (0.36–0.98) | (Ref) |